Alzamend Neuro (NASDAQ:ALZN) Director Milton Ault III Sells 20,686 Shares of Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 20,686 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $2.39, for a total transaction of $49,439.54. Following the transaction, the director owned 74,163 shares of the company’s stock, valued at $177,249.57. This trade represents a 21.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alzamend Neuro Trading Up 2.4%

NASDAQ ALZN opened at $2.53 on Friday. Alzamend Neuro, Inc. has a 52 week low of $2.06 and a 52 week high of $17.10. The firm has a 50 day moving average of $2.40 and a two-hundred day moving average of $4.11.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC bought a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned approximately 0.56% of Alzamend Neuro at the end of the most recent quarter. Institutional investors and hedge funds own 49.61% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. Wall Street Zen cut shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Weiss Ratings reiterated a “sell (e)” rating on shares of Alzamend Neuro in a report on Saturday, September 27th. Finally, Ascendiant Capital Markets lowered their price target on shares of Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, September 25th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alzamend Neuro presently has a consensus rating of “Hold” and a consensus target price of $42.00.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.